226 related articles for article (PubMed ID: 33189635)
41. Impact of mitral regurgitation in patients with acute heart failure: insights from the RELAX-AHF-2 trial.
Pagnesi M; Adamo M; Ter Maaten JM; Beldhuis IE; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Pang PS; Ponikowski P; Sama IE; Severin T; Gimpelewicz C; Voors AA; Teerlink JR; Metra M
Eur J Heart Fail; 2023 Apr; 25(4):541-552. PubMed ID: 36915227
[TBL] [Abstract][Full Text] [Related]
42. Worsening Heart Failure Following Admission for Acute Heart Failure: A Pooled Analysis of the PROTECT and RELAX-AHF Studies.
Davison BA; Metra M; Cotter G; Massie BM; Cleland JGF; Dittrich HC; Edwards C; Filippatos G; Givertz MM; Greenberg B; Ponikowski P; Voors AA; O'Connor CM; Teerlink JR;
JACC Heart Fail; 2015 May; 3(5):395-403. PubMed ID: 25951761
[TBL] [Abstract][Full Text] [Related]
43. Association of Early Blood Pressure Decrease and Renal Function With Prognosis in Acute Heart Failure.
Matsue Y; Sama IE; Postmus D; Metra M; Greenberg BH; Cotter G; Davison BA; Felker GM; Filippatos G; Pang P; Ponikowski P; Severin T; Gimpelewicz C; Voors AA; Teerlink JR
JACC Heart Fail; 2021 Dec; 9(12):890-903. PubMed ID: 34627724
[TBL] [Abstract][Full Text] [Related]
44. Population pharmacokinetics of serelaxin in patients with acute or chronic heart failure, hepatic or renal impairment, or portal hypertension and in healthy subjects.
Soubret A; Pang Y; Yu J; Dahlke M
Br J Clin Pharmacol; 2018 Nov; 84(11):2572-2585. PubMed ID: 30014598
[TBL] [Abstract][Full Text] [Related]
45. Association of left ventricular ejection fraction with worsening renal function in patients with acute heart failure: insights from the RELAX-AHF-2 study.
Feng S; Janwanishstaporn S; Teerlink JR; Metra M; Cotter G; Davison B; Felker GM; Filippatos G; Pang P; Ponikowski P; Sama IE; Voors AA; Greenberg B
Eur J Heart Fail; 2021 Jan; 23(1):58-67. PubMed ID: 32964537
[TBL] [Abstract][Full Text] [Related]
46. Relaxin: a novel agent for the treatment of acute heart failure.
Wilson SS; Ayaz SI; Levy PD
Pharmacotherapy; 2015 Mar; 35(3):315-27. PubMed ID: 25759289
[TBL] [Abstract][Full Text] [Related]
47. Serelaxin, recombinant human relaxin-2, for heart failure patients: A systematic review and meta-analysis.
Yu L; Cao L; Sun J; Li Z; Yao F; Zhou Y
Medicine (Baltimore); 2018 Jun; 97(25):e11010. PubMed ID: 29923986
[TBL] [Abstract][Full Text] [Related]
48. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure.
Ponikowski P; Kirwan BA; Anker SD; Dorobantu M; Drozdz J; Fabien V; Filippatos G; Haboubi T; Keren A; Khintibidze I; Kragten H; Martinez FA; McDonagh T; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Jankowska EA
Eur J Heart Fail; 2019 Dec; 21(12):1651-1658. PubMed ID: 31883356
[TBL] [Abstract][Full Text] [Related]
49. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study.
Teerlink JR; Metra M; Felker GM; Ponikowski P; Voors AA; Weatherley BD; Marmor A; Katz A; Grzybowski J; Unemori E; Teichman SL; Cotter G
Lancet; 2009 Apr; 373(9673):1429-39. PubMed ID: 19329178
[TBL] [Abstract][Full Text] [Related]
50. Renal hemodynamic effects of serelaxin in patients with chronic heart failure: a randomized, placebo-controlled study.
Voors AA; Dahlke M; Meyer S; Stepinska J; Gottlieb SS; Jones A; Zhang Y; Laurent D; Slart RH; Navis GJ
Circ Heart Fail; 2014 Nov; 7(6):994-1002. PubMed ID: 25286914
[TBL] [Abstract][Full Text] [Related]
51. Renal impairment and worsening of renal function in acute heart failure: can new therapies help? The potential role of serelaxin.
Schmieder RE; Mitrovic V; Hengstenberg C
Clin Res Cardiol; 2015 Aug; 104(8):621-31. PubMed ID: 25787721
[TBL] [Abstract][Full Text] [Related]
52. Relationship between left ventricular ejection fraction and cardiovascular outcomes following hospitalization for heart failure: insights from the RELAX-AHF-2 trial.
Janwanishstaporn S; Feng S; Teerlink J; Metra M; Cotter G; Davison BA; Felker GM; Filippatos G; Pang P; Ponikowski P; Severin T; Gimpelewicz C; Holbro T; Chen CW; Sama I; Voors AA; Greenberg BH
Eur J Heart Fail; 2020 Apr; 22(4):726-738. PubMed ID: 32141161
[TBL] [Abstract][Full Text] [Related]
53. Impact of diabetes on mortality and rehospitalization in acute heart failure patients stratified by ejection fraction.
Al-Jarallah M; Rajan R; Al-Zakwani I; Dashti R; Bulbanat B; Ridha M; Sulaiman K; Alsheikh-Ali AA; Panduranga P; AlHabib KF; Al Suwaidi J; Al-Mahmeed W; AlFaleh H; Elasfar A; Al-Motarreb A; Bazargani N; Asaad N; Amin H
ESC Heart Fail; 2020 Feb; 7(1):297-305. PubMed ID: 31825180
[TBL] [Abstract][Full Text] [Related]
54. Hepatorenal dysfunction identifies high-risk patients with acute heart failure: insights from the RELAX-AHF trial.
Biegus J; Demissei B; Postmus D; Cotter G; Davison BA; Felker GM; Filippatos G; Gimpelewicz C; Greenberg B; Metra M; Severin T; Teerlink JR; Voors AA; Ponikowski P
ESC Heart Fail; 2019 Dec; 6(6):1188-1198. PubMed ID: 31568696
[TBL] [Abstract][Full Text] [Related]
55. Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection Fraction: Results From the ROSE AHF Trial (Renal Optimization Strategies Evaluation in Acute Heart Failure).
Wan SH; Stevens SR; Borlaug BA; Anstrom KJ; Deswal A; Felker GM; Givertz MM; Bart BA; Tang WH; Redfield MM; Chen HH
Circ Heart Fail; 2016 Aug; 9(8):. PubMed ID: 27512103
[TBL] [Abstract][Full Text] [Related]
56. Blood Pressure Drops During Hospitalization for Acute Heart Failure Treated With Serelaxin: A Patient-Level Analysis of 4 Randomized Controlled Trials.
Grand J; Miger K; Sajadieh A; Køber L; Torp-Pedersen C; Ertl G; López-Sendón J; Pietro Maggioni A; Teerlink JR; Sato N; Gimpelewicz C; Metra M; Holbro T; Nielsen OW
Circ Heart Fail; 2022 Apr; 15(4):e009199. PubMed ID: 35184572
[TBL] [Abstract][Full Text] [Related]
57. Recent developments in the treatment of heart failure: highlights from the American Heart Association's Scientific Sessions, Los Angeles, California, 3 - 7 December 2012.
von Haehling S
Expert Opin Investig Drugs; 2013 Jul; 22(7):933-7. PubMed ID: 23656525
[TBL] [Abstract][Full Text] [Related]
58. Safety and tolerability of serelaxin, a recombinant human relaxin-2 in development for the treatment of acute heart failure, in healthy Japanese volunteers and a comparison of pharmacokinetics and pharmacodynamics in healthy Japanese and Caucasian populations.
Dahlke M; Ng D; Yamaguchi M; Machineni S; Berger S; Canadi J; Rajman I; Lloyd P; Pang Y
J Clin Pharmacol; 2015 Apr; 55(4):415-22. PubMed ID: 25408331
[TBL] [Abstract][Full Text] [Related]
59. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.
O'Connor CM; Miller AB; Blair JE; Konstam MA; Wedge P; Bahit MC; Carson P; Haass M; Hauptman PJ; Metra M; Oren RM; Patten R; Piña I; Roth S; Sackner-Bernstein JD; Traver B; Cook T; Gheorghiade M;
Am Heart J; 2010 May; 159(5):841-849.e1. PubMed ID: 20435194
[TBL] [Abstract][Full Text] [Related]
60. Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre-RELAX-AHF.
Voors AA; Davison BA; Felker GM; Ponikowski P; Unemori E; Cotter G; Teerlink JR; Greenberg BH; Filippatos G; Teichman SL; Metra M;
Eur J Heart Fail; 2011 Sep; 13(9):961-7. PubMed ID: 21622980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
